1 The mechanism of action of sumatriptan on coronary¯ow was examined before and after two dierent forms of endothelial ablation in guinea-pig isolated hearts. The mechanism was assessed in terms of the in¯uence of the integrity of the coronary endothelium, the role of release of nitric oxide (NO) from the endothelium, and the receptor subtypes mediating the eects. 2 Continuous perfusion with sumatriptan reduced coronary¯ow, but the concentration-response curve was v-shaped. Sumatriptan (0.001 ± 0.1 mM) caused a concentration-dependent decrease in coronary¯ow with the maximum eect achieved at 0.23+0.04 mM. The pEC 50 was 8.49+0.07. At higher concentrations (0.1 ± 10 mM) there was a concentration-dependent diminution of the vasoconstrictor eect. Endothelial ablation by saponin removed the diminution in the vasoconstrictor eect. In contrast, pretreatment with N G -nitro L-arginine methyl ester (L-NAME) (100 mM, 45 min perfusion) did not aect it. This was despite both saponin and L-NAME being eective in reducing basal release of NO into the coronary euent (measured by chemiluminescence) to the same extent (71+3 and 73+2%, respectively). 3 GR127935, a selective 5-hydroxytryptamine 1D (5-HT 1D ) receptor antagonist (3 and 10 nM), which by itself had no eect on coronary¯ow or NO release, antagonized the vasoconstrictor response to sumatriptan and unmasked a sumatriptan-induced concentration-dependent increase in coronary¯ow and NO release. These increases in coronary¯ow and NO release were abolished by pretreatment with either saponin or L-NAME. 4 Mesulergine, a 5-HT 2 receptor antagonist which had no eect by itself on basal coronary¯ow or NO release, inhibited the vasodilator response to sumatriptan that occurred in the presence of GR127935, and actually enhanced the vasoconstrictor response, increasing the maximum fall in coronary¯ow from 73.9+0.4 to 75.2+0.4 ml min 71 g 71 (P50.05). The diminution of vasoconstrictor eect of sumatriptan was abolished by mesulergine and by pretreatment with saponin, but not by L-NAME. 5 In conclusion, guinea-pig coronary arteries constrict to low concentrations of sumatriptan, causing a reduction in coronary¯ow. This eect appears to be caused by 5-HT 1D agonism with the receptors located on the coronary vascular smooth muscle. With higher concentrations of sumatriptan this is partially oset by a weaker vasodilator eect, which is caused by low anity 5-HT 2 agonism. Although this eect is endothelium-dependent, it is not caused by the release of NO. Interestingly, when the vasoconstrictor eect of sumatriptan was inhibited by the 5-HT 1D antagonist GR127935, a high anity vasodilator eect of sumatriptan was unmasked. This is 5-HT 2 receptor mediated and is caused by release of NO from the coronary endothelium. 6 In man, sumatriptan and 5-HT may both be capable of causing pathogenic coronary vasoconstriction. The implications of the present data are that the scope for this may depend greatly on (i) the extent of underlying endothelial dysfunction, (ii) the extent of endothelial 5-HT 2 receptormediated release of vasodilator autacoids (which include NO) and (iii) the extent of smooth muscle 5-HT 1D receptor-mediated vasoconstriction.
Introduction 5-Hydroxytryptamine (5-HT) released by platelets has been suggested to play a role in coronary artery spasm associated with thrombosis (Golino et al., 1989; van den Berg et al., 1989; Noble & Drake-Holland 1990; Bax et al., 1993) . 5-HT may constrict human atherosclerotic coronary arteries (McFadden et al., 1991; Golino et al., 1991) and may precipitate variant angina and myocardial infarction (Hillis & Lange 1991) . On the other hand, 5-HT may dilate healthy coronary arteries (Golino et al., 1991) . Chester et al. (1993) demonstrated the conversion of a mild coronary dilatation in response to an intracoronary injection of 5-HT in healthy coronary arteries to a vasoconstriction in patients with atherosclerosis and clinical symptoms of coronary artery disease. Constriction of human coronary arteries has been suggested to occur via the activation of 5-HT 2 receptors (Connor et al., 1989; Toda & Okomura, 1990) . However, the pathogenic relevance of this is questionable since the speci®c 5-HT 2 antagonist, ketanserin, is not effective in the treatment of angina (De Caterina et al., 1984; Freedman et al., 1984) . A ketanserin-resistant 5-HT-induced constriction occurs in human coronary arteries in vivo (McFadden et al., 1992) and in vitro (Kaumann & Brown, 1990) , occurring as a consequence of 5-HT 1 -like agonism (`like' denotes that the receptor subtype is uncertain). In view of these observations, Chester et al. (1993) suggested that the relative importance of 5-HT 2 and 5-HT 1 -like receptors in mediating 5-HT-induced coronary constriction may change in coronary artery disease.
In addition to the unresolved role of endogenous 5-HT as mediator of pathogenic coronary vasoconstriction, 5-HT receptor-mediated coronary vasospasm has potential relevance to the safety of receptor type-and subtype-selective synthetic 5-hydroxytryptamine mimetics. The anti-migraine drug su-matriptan, a relatively selective 5-HT 1D agonist (Humphrey et al., 1988; Peroutka & McCarthy, 1989) has been shown to reduce coronary artery diameter during angioplasty (MacIntyre et al., 1993) , and can cause chest pain and cardiac ischaemia (Willett et al., 1992) and even myocardial infarction (Ottervanger et al., 1993) . Sumatriptan constricts human coronary arteries in vitro (Bax et al., 1993; Cocks et al., 1993; Kaumann et al., 1993) and in vivo (MacIntyre et al., 1992) , constricts dog saphenous vein in vitro (Humphrey et al., 1988) and constricts dog coronary arteries in vitro (Parsons et al., 1992) and in vivo (Fenuik et al., 1989; Saxena & Villalon 1990; Humphrey et al., 1991) . It also constricts guinea-pig iliac artery (Sahin-Erdemli et al., 1991; Schoeter & Sahin-Erdemli, 1992) and rabbit coronary artery (Feletou et al., 1994) . In contrast, pig coronary arteries and guinea-pig jugular veins relax to sumatriptan via an endothelium-dependent mechanism (Schoeter & Hoyer, 1990; Gupta, 1992) . The cardiac safety of receptor type-and subtype-speci®c 5-HT mimetics will depend on the scope for receptor type-and subtype-dependent coronary constriction (i.e., the magnitude of the response, its dependence on endothelial integrity, and its receptor subtype dependence). These issues remain contentious.
The demonstration of 5-HT-induced vasoconstriction or vasodilatation in isolated vascular tissue is not necessarily predictive of the response in vivo (Cambridge et al., 1995) . Moreover, 5-HT receptor-mediated responses show a remarkable degree of heterogeneity both between species and between dierent tissues within the same species. For example, in cat heart, arteries larger than 90 mm constrict to 5-HT, whereas those smaller than 90 mm dilate to 5-HT (Lamping et al., 1989) . In the rabbit microcirculation the 5-HT 2 receptors appear to be most important in mediating vasoconstriction, whereas in large arteries 5-HT 1 -like receptors appear to be more important (Feletou et al., 1994) .
We have previously shown an increase in coronary¯ow in guinea-pig isolated heart (endothelium intact) in response to 5-HT. This vasodilatation was abolished, although not converted to a vasoconstriction, by endothelial denudation with saponin (Ellwood & Curtis, 1996a) . In view of the need to characterize further the vascular pharmacology of the 5-HT receptor-response system in guinea-pig coronaries, and in order to examine the determinants and mechanism of action of sumatriptan on coronary¯ow, the aim of the present study was to investigate the eect of endothelial denudation and NO synthase inhibition by N G -nitro-L-arginine methyl ester (L-NAME) on the responses to sumatriptan in guinea-pig perfused, isolated hearts. The selective 5-HT 1D antagonist GR127935 (Skingle et al., 1993) and the 5-HT 2 receptor antagonist mesulergine (Closse, 1983; Pazos et al., 1985) were used as tools to probe the receptor types responsible for the complex actions of sumatriptan.
Some of the present ®ndings have been presented to the British Pharmacological Society (Ellwood & Curtis, 1996b, c) .
Methods
All experiments were performed in accordance with the United Kingdom Home Oce`Guide on the Operation of the Animals (Scienti®c Procedures) Act 1986'. Male Dunkin Hartley guineapigs (Charles River, Kent, 350 ± 400 g) were terminally anaesthetized with sodium pentobarbitone (60 mg kg 71 , i.p.) and treated with heparin (sodium heparin, 250 iu, i.p.). The chests were opened and the hearts quickly excised and placed in icecold perfusion solution (constituents below). The hearts were cannulated via the aorta (Langendor mode) within 90 s of removal. Hearts were perfused under constant pressure (100 cmH 2 O) with modi®ed Krebs solution containing (mM): glucose 11.1, CaCl 2 1.4, NaCl 118.5, NaHCO 3 25.0, MgSO 4 1.2, NaH 2 PO 4 1.2 and KCl 4.0. This was made with ultra pure water (reverse osmosis, Milli RO-50, Watford, U.K.) and was vacuum ®ltered (5 micron ®lter paper, Millipore, Watford, U.K.) to remove particulate coronary spasmogens.
The modi®ed Krebs solution was gassed with 95% O 2 and 5% CO 2 , pH 7.4 and delivered at 378C. To eliminate any eect that change in heart rate may have on coronary¯ow, hearts were paced via the left ventricle (stimulus pulse width 0.5 m s 71 ) at a rate of 275 beats min 71 , by a Harvard student stimulator (Edenbridge, U.K.). Heart rate was veri®ed from a unipolar electrogram with one electrode placed in the left ventricle and a second attached to the aortic cannula. This was recorded on a Grass polygraph (model RPS 7C8, Quincy, MA, U.S.A.).
Coronary¯ow measurement
Coronary¯ow was measured either by weighing (1 ml=1 g) coronary euent with an Ohaus balance (Cambridge, U.K.), accurate to 1 mg (Rees & Curtis, 1993) , following timed collection of the euent, or by the use of an in-line ultrasonic¯ow probe (Park et al., 1992 ; Transonic Systems, Diss, U.K.). Three consecutive measurements were taken during the last 90 s of drug perfusion and the mean was calculated. Coronarȳ ow increases and decreases, calculated ®rst as positive or negative ml min 71 g 71 wet weight of the ventricle, were expressed as positive or negative % changes from baseline (%D coronary¯ow).
Following cannulation the hearts were allowed to stabilize for 30 min or until 3 consecutive coronary¯ow measurements were within 0.4 ml min ±1 . The study protocol was then commenced. Hearts were excluded from analysis and were replaced if the coronary¯ow was less than 8 ml g 71 min 71 at the beginning of the study protocol. All agonists were delivered continuously by perfusion for a set time period (6 min) and cumulative concentration-response curves were constructed by switching between separate perfusion reservoirs.
Endothelial denudation and NO inhibition
The ®rst groups of hearts were perfused with L-NAME, saponin or neither. For L-NAME, 100 mM was delivered for 45 min (n=24). This concentration and duration of perfusion have previously been shown to inhibit substantially the basal release of NO (Pabla & Curtis, 1995) . For saponin, 30 mg ml 71 was delivered in three cycles of 2 min followed by 2 min Krebs perfusion, followed by a 33 min control perfusion (n=24). This protocol has been shown to reduce substantially the basal release of NO and abolish agonist-induced endotheliummediated coronary dilatation and NO release without aecting endothelium independent constriction or dilatation in this preparation (Ellwood & Curtis, 1996a; Wiest et al., 1989) . In hearts perfused with neither L-NAME nor saponin, a time matched perfusion of Krebs solution was delivered for 45 min (n=39). The adequacy of the L-NAME and saponin protocols was tested by 5 min perfusion with either 1 mM ACh or 10 nM substance P (Furchgott, 1983) , and hearts were excluded from the study if they exhibited an increase in coronary¯ow.
All hearts were then perfused for 15 min with one of the following: vehicle (Krebs solution, n=39), 3 nM GR127935 (n=13), 10 nM GR127935 (n=36), 3 mM mesulergine (n=18) or both 3 mM mesulergine and GR127935 (3 nM, n=6 or 10 nM, n=18). In the continued presence of these solutions, the hearts then received incremental concentrations of sumatriptan (0.1 nM to 10 mM). A total of 87 hearts was used (with 4 exclusions).
To test for time-dependent run down in the absence of L-NAME or saponin, time-matched controls (n=5) received vehicle over the same time course (153 min). To test for nonspeci®c eects of 5-HT antagonists, hearts were perfused with 10 nM GR127935 (n=6) or 3 mM mesulergine (n=6) for 153 min, in the absence of L-NAME, saponin or sumatriptan.
Measurement of NO release by chemiluminescence
The NO released from the guinea-pig isolated hearts was measured by the method described by Menon et al. (1989) , with a Sievers NO analyser (model number 270B, Dyson Instruments, Hetton, U.K.). It has been used successfully in isolated perfused hearts in our laboratory (Pabla & Curtis, 1995) . This method is based on a gas phase chemiluminescence reaction between NO and ozone:
The chemiluminescence was detected by a photomultiplier. The output was processed and recorded by a Mac Lab computer (model 2E, AD Instruments, Hastings, U.K.). A 1 ml aliquot of coronary euent collected during the last 90 s of drug perfusion was decanted into a plastic Eppendorf tube (BDH Laboratory supplies, Dagenham, U.K.) and immediately frozen in liquid nitrogen, and stored at 7208C. Subsequently the samples were thawed and analysed. The NO in the coronary euent undergoes autoxidation to nitrite (Kelm & Schrader, 1990) , so the samples were injected into a purge vessel containing a reducing solution (1% potassium iodide and glacial acetic acid). An inert gas (helium) was used to¯ush the NO under reduced pressure into the NO analyser. The NO content of the samples was calculated by using a standard curve derived from reducing known quantities of sodium nitrite in the purge vessel. Krebs was used to make up the standards to allow for any contaminant nitrite present in the chemical constituents of the perfusion solution. NO content was expressed as pmol g 71 min 71 wet weight of perfused cardiac tissue (Pabla & Curtis, 1995) .
Drugs
Saponin and L-NAME were obtained from Sigma Chemicals, Poole, U.K. Sumatriptan, mesulergine and
Data handling and statistics
Concentration-response curves were constructed for individual preparations and, from each, the maximum response, concentration evoking the maximum response and EC 50 values were read o. Group mean+s.e.mean were calculated from these values and it is these that have been plotted in the ®gures. Comparisons were made by an ANO-VA, followed by an unpaired t-test, modi®ed by Dunnett's correction for multiple comparisons where appropriate. A P value50.05 was considered to be statistically signi®cant.
Results

Coronary¯ow and NO release during drug free perfusion
There was a small time-dependent decline in coronary¯ow and coronary euent NO content in the time matched (drug-free perfusion) control hearts. Since this was small compared to drug eects (see below) it has not been taken into consideration when determining drug eects. At time zero (equivalent to the start of the agonist protocol) the mean coronary¯ow and NO were 11.4+0. The eect of mesulergine and GR127935 on coronarȳ ow and NO release in the absence of sumatriptan Continuous delivery of 3 mM mesulergine or 10 nM GR127935 had no eect on basal coronary¯ow or basal NO release, indicating that these 5-HT antagonists were devoid of nonspeci®c activity in the preparation. In these groups there was a time-dependent fall in coronary¯ow and NO release which was similar to that seen in time-matched drug-free control hearts (data not shown).
The eect of sumatriptan on coronary¯ow and NO release
The action of sumatriptan on coronary¯ow was v-shaped ( Figure 1a) . At up to 0.1 mM, there was a concentration-dependent decrease in coronary¯ow. The concentration producing the maximum constrictor response was 0.13+0.04 mM, and the pEC 50 was 8.49+0.07. At concentrations above 0.1 mM, the decrease in coronary¯ow diminished (Figure 1a) . Thus sumatriptan possessed a high anity vasoconstrictor action and a lower anity vasodilator action, with constriction predominating. Neither of these eects was accompanied by Eect of GR127935 on responses to sumatriptan GR127935 abolished the decrease in coronary¯ow caused by sumatriptan and converted the response into a concentrationdependent¯ow increase. This newly unmasked coronary dilator action was signi®cant at concentrations of sumatriptan between 0.1 nM and 10 mM (Figure 1a) . The concentration evoking the maximum dilator response was 0.02+0.004 mM, and the pEC 50 was 9.01+0.12. GR127935 also unmasked a concentration-dependent ability of sumatriptan to increase coronary euent NO content (Figure 1b) . This NO release occurred in parallel with the increase in the coronary¯ow. The eects of 3 nM GR127935 on the actions of sumatriptan were almost indistinguishable from the eects of 10 nM.
Eects of mesulergine on responses to sumatriptan
Mesulergine had the opposite eect to that of GR127935. It exacerbated the vasoconstrictor response to sumatriptan ( Figure 2a ). Moreover, it abolished the diminution of the constrictor eect previously seen with high concentrations of sumatriptan (0.3 to 10 mM) such that the concentration of sumatriptan producing the maximum constrictor response was signi®cantly increased to 0.73+0.6 mM. Thus the sumatriptan concentration-response relationship became monophasic (Figure 2a) . Furthermore, the magnitude of the reduction in coronary¯ow caused by each concentration of sumatriptan was signi®cantly increased by mesulergine. However, the pEC 50 remained unchanged. Coronary euent NO content, unchanged by sumatriptan alone, was again found not to be signi®cantly changed by sumatriptan when administered in the presence of mesulergine (Figure 2b ).
Eects of GR127935 plus mesulergine on responses to sumatriptan
PR127935 (3 and 10 mM) reduced, in a concentration-dependent manner, the ability of mesulergine to exacerbate sumatriptan-induced vasoconstriction. Thus at each concentration of sumatriptan, the reduction in coronary¯ow was approximately halved by 3 nM GR127935 and was abolished completely by 10 nM GR127935 (Figure 2a ). The sumatriptan concentration-response relationship, converted from v-shaped to sigmoidal by mesulergine, remained monophasic with the addition of 3 nM GR127935. In the presence of mesulergine and mesulergine combined with GR127935 the pEC 50 s to sumatriptan were 8.6+0.1 and 7.9+0.1, respectively. Coronary NO content remained unchanged by sumatriptan in the presence of GR127935 plus mesulergine (Figure 2b ).
Eects of L-NAME and saponin on basal coronary¯ow and NO release
Saponin signi®cantly reduced basal coronary¯ow by a small amount, 1.4+0.3 ml g 71 min 71 (P50.05, n=24, Figure 3a ), i.e., 711+2%. This, nevertheless, was accompanied by a large reduction in basal NO release of 71+3% (P50.05, Figure 3b ). L-NAME reduced basal coronary¯ow by a more substantial 4.4+0.4 ml min 71 g 71 (P50.05, Figure 3a) , i.e., 739+3%, which was signi®cantly greater than the reduction caused by saponin (P50.05). L-NAME also reduced basal NO content but only by 73+2%, an eect similar to that caused by saponin (P50.05, Figure 3b ).
Eects of sumatriptan following L-NAME and saponin pretreatment L-NAME pretreatment did not alter the v-shaped coronary constrictor eect of sumatriptan in any way (Figure 4) . In contrast, saponin abolished the diminution of the vasoconstriction that occurred with higher concentrations of sumatriptan. In fact, the response to sumatriptan over the 0. , n=8) , in the presence of 3 mM mesulergine (solid columns, n=8) or 3 mM mesulergine plus 3 nM GR127935 (hatched columns, n=7), or 3 mM mesulergine plus 10 nM GR127935 (stippled columns, n=6). Data are mean+s.e.mean, *P50.05 versus sumatriptan alone, **P50.05 versus sumatriptan plus 3 mM mesulergine, {P50.05 versus sumatriptan plus 3 mM mesulergine and sumatriptan plus 3 mM mesulergine plus 3 nM GR127935.
at 1 mM, P50.05). The pEC 50 s to sumatriptan following L-NAME and saponin were 8.58+0.12 and 8.52+0.14, respectively.
Eects of mesulergine on responses to sumatriptan following L-NAME and saponin pretreatment
Following pretreatment with L-NAME, there was no change in the coronary constrictor response to sumatriptan administered in the presence of mesulergine ( Figure 5) . Thus, the concentrations of sumatriptan (in the presence of mesulergine) producing the maximum constrictor responses were 0.29+0.12 mM and 0.28+0.09 mM, respectively. In contrast, saponin caused a signi®cant enhancement (at the top end of the concentration-response curve) of the contractile response to sumatriptan in the presence mesulergine ( Figure 5 ). The concentration of sumatriptan producing the maximum constrictor response (in the presence of mesulergine) following saponin was 0.97+0.11 mM (P50.05, versus no saponin). Saponin abolished the diminution of the reduction in coronary¯ow with high concentrations of sumatriptan. This caused an increase in the concentration of sumatriptan producing the maximum constrictor response to 6.7+1.3 mM. ) Figure 3 The eect of a 45 min perfusion with 100 mM L-NAME (open columns, n=24) or a 30 mg ml 71 saponin protocol (solid columns, n=24) on (a) coronary¯ow expressed as % change from baseline (%D coronary¯ow), and (b) coronary euent NO content expressed as change from baseline (DNO). Data are mean+s.e.mean. *P50.05 versus before L-NAME or saponin treatment; **P50.05 versus the L-NAME group. , following 100 mM L-NAME pretreatment (solid columns, n=6), or a 30 mg ml 71 saponin protocol (hatched columns, n=6). Data are mean+s.e.mean. *P50.05 versus sumatriptan combined with mesulergine.
Eect of GR127935 on responses to sumatriptan following L-NAME and saponin L-NAME pretreatment abolished the vasodilatation caused by sumatriptan in the presence of GR127935 at the lower end of the sumatriptan concentration-response curve (0.3 nM to 0.1 mM; Figure 1a) , revealing a small vasoconstriction ( Figure  6a ). This was accompanied by inhibition of sumatriptan-induced NO release (Figure 6b ). At concentrations of sumatriptan above 0.3 mM in the presence of GR127935, there was a signi®cant, though insubstantial, vasodilatation (Figure 6a) .
Pretreatment with saponin ( Figure 7a ) completely abolished the vasodilatation caused by sumatriptan in the presence of GR127935 (Figure 1a) . In contrast to L-NAME, this eect was found over the full range of sumatriptan concentrations. The eect was accompanied by an inhibition of NO release ( Figure  7b) , although, interestingly, saponin did not cause a signi®cant decrease in NO release with the lowest concentration of sumatriptan (0.1 nM) compared to control. This eect was partially inhibited by GR127935 (Figure 7b ). Eects of GR127935 plus mesulergine on responses to sumatriptan following L-NAME and saponin Sumatriptan, when administered in the presence of 10 nM GR127935 and 3 mM mesulergine had been found previously to have no eect on coronary¯ow (Figure 2a) or NO (Figure 2b ). This response was not aected by pretreatment with either L-NAME (Figure 8) or saponin (Figure 9 ).
Discussion
We examined the actions of sumatriptan on coronary¯ow and NO release in the guinea-pig isolated heart. Sumatriptan has been shown to be a selective 5-HT 1D agonist (Peroutka & McCarthy, 1989; Schoeter & Hoyer, 1989) tively; Hoyer et al., 1994) . In addition, sumatriptan has some activity at 5-HT 2C receptors (pEC 50 =4. 3, Hoyer et al., 1994) . The nature of the receptors responsible for the action of sumatriptan on coronary vasculature and the role of the endothelium in modulating these actions were examined in the present study. There is evidence that there are two distinct 5-HT receptors involved in endothelium-dependent vasodilatation. In the pig coronary artery and the guinea-pig jugular vein the receptor involved appears to be of the 5-HT 1D subtype (Schoeter & Hoyer, 1990; Gupta, 1992) . In other tissues such as the rabbit jugular vein, pig vena cava, pig pulmonary artery and rat jugular vein the receptors involved appear not to be of the 5-HT 1 -like subtype (Le et al., 1987) , but share some pharmacological features in common with the 5-HT 2 receptor class (Martin et al., 1993) , and may be of the 5-HT 2B or 5-HT 2C subtype (Martin et al., 1993; Glusa & Richter, 1993; Bodelsson et al., 1993; Ellis et al., 1995) . At least two subtypes of receptor, and at least two endothelial autacoids (one of which is NO) were found to regulate the nature and extent of the actions of sumatriptan in the present study. The predominant eect was vasoconstriction, but this was made worse when two dierent endothelium-dependent vasodilator mechanisms were inhibited by endothelial ablation.
Actions of sumatriptan on coronary¯ow and NO release
In endothelium-intact guinea-pig hearts, sumatriptan caused a high anity concentration-dependent reduction in coronarȳ ow. This constrictor response was v-shaped and, at higher concentrations, the vasoconstriction diminished, indicative of a low anity vasodilator eect (that was not mediated by NO). The v-shaped contractile response pro®le was similar to that shown for dog isolated coronary arteries (Parsons et al., 1992) .
GR127935, which is a potent highly selective 5-HT 1D receptor antagonist (Skingle et al., 1993) , inhibited the reduction in coronary¯ow caused by sumatriptan. In addition GR127935 unmasked a high anity coronary vasodilator action of sumatriptan which was accompanied by an increase in coronary euent NO content.
Mesulergine removed the diminution of the vasoconstrictor eect of high concentrations of sumatriptan and blocked sumatriptan-induced NO release. Mesulergine has 5-HT 2A , 5-HT 2B and 5-HT 2C antagonist activity (Hoyer et al., 1994) , so sumatriptan may have activity on coronary 5-HT 2 receptors (Schoeter & Hoyer, 1989) . The present data support this suggestion and reveal that 5-HT 2 agonism contributes to the eects of sumatriptan on coronary¯ow.
The present data suggest that in endothelium-intact hearts, sumatriptan initiates a high anity 5-HT 1D -receptor-mediated coronary constriction (blocked by GR127935) that masks (and apparently prevents the operation of) a high anity, NOmediated vasodilator action. The constrictor action appears to be attenuated slightly by a low anity, NO-independent 5-HT 2 receptor-mediated vasodilator action (blocked by mesulergine). However, both the high and low anity vasodilator actions of sumatriptan were eectively overwhelmed by the predominant constrictor action of 5-HT, and were unmasked only after administration of the 5-HT 1D receptor antagonist, GR127935. To examine these complex actions further, we used two techniques to isolate the role of the endothelium and NO release in modulating the actions of sumatriptan.
Role of endothelium and NO in mediating the latent vasodilator action of sumatriptan
The low anity vasodilator action of sumatriptan was not aected by L-NAME (Figure 4 ), con®rming that it was not mediated by NO. However, saponin abolished this vasodilatation. The saponin protocol used has previously been found to abolish vasodilatation to substance P without aecting the response to sodium nitroprusside (Ellwood & Curtis, 1996a) . Thus, the low anity vasodilator action of sumatriptan that is blocked by the 5-HT 2 antagonist, mesulergine, requires an intact coronary endothelium, but is not mediated by NO. Additionally, saponin (though not L-NAME) exacerbated the ability of mesulergine to facilitate sumatriptan-induced vasoconstriction over the concentration range at which sumatriptan alone induced a low anity coronary vasodilatation. This further supports the evidence that the low anity sumatriptan-induced vasodilatation is caused by agonism at 5-HT 2 receptors that are present on the coronary endothelium. However, it also demonstrates that NO is not the intercellular autacoid responsible for mediating this eect.
In contrast, the high anity vasodilator action of sumatriptan, revealed in the presence of GR127935, was almost completely abolished by L-NAME and saponin (Figures 6 and  7) , con®rming that it was mediated by endothelium-dependent NO release. Interestingly, the high anity vasodilator action of sumatriptan was also abolished by mesulergine. This suggests that 5-HT 2 agonism elicits both a high anity NO release and a low anity release of a dierent vasodilator substance from the guinea-pig coronary endothelium. Presumably different 5-HT 2 receptor subtypes are involved in these responses, although we have no evidence yet to discriminate between the three options (2A, 2B and 2C).
Possible limitations of the present study
The predominant action of sumatriptan on coronary¯ow in the guinea-pig endothelium-intact heart is a GR127935-sensitive coronary vasoconstriction. This action is not blocked by saponin and thus represents a direct action on coronary smooth muscle rather than an indirect eect mediated by the release of an autacoid from the endothelium. However, to deduce that this action is mediated by 5-HT 1D receptors depends on the selectivity of GR127935. GR127935 has been shown to be a partial agonist of 5-HT 1Da receptors at concentrations above 10 nM in cultured cell lines (Watson et al., 1995; . However, Skingle et al. (1996) argued that the transfection of high numbers of 5-HT 1D receptors (5-HT 1Da and 5-HT 1Db subtypes) in to cell lines may lead to overestimation of the extent to which GR127935 is a partial agonist. In the present study, 10 nM GR127935 had no eect alone on coronary¯ow or NO release, which would suggest that GR127935 does not act as a partial agonist in guinea-pig coronary artery. Thus, there is no evidence that GR127935 does anything other than block 5-HT 1D receptors over the concentration range that possessed activity in the present study. On this basis, it would appear reasonable to deduce that the predominant constrictor action of sumatriptan was mediated by agonism at 5-HT 1D receptors located on the coronary smooth muscle.
The predominant eect of sumatriptan in saponin-treated hearts was a monophasic coronary constriction larger than that observed in endothelium-intact hearts. This eect was also blocked by GR127935. Endothelial injury is therefore likely to enhance any potentially hazardous coronary constriction that sumatriptan may elicit, by shifting the balance in favour of the 5-HT 1D receptor-mediated actions. However, we are tempted to conclude that this is likely to be mediated not simply by the physical exposure of smooth muscle 5-HT 1D receptors in the coronary lumen. There are two reasons for this deduction. First, the mechanism is evidently extant when the endothelium is intact. Second, it is enhanced by manoeuvres that reduce endothelial autacoid release. Thus the impairment of 5-HT receptor-mediated endothelially-derived vasodilator autacoid release is likely to contribute to the greater scope for sumatriptan to constrict coronary arteries after endothelial injury. We have suggested that this involves loss of endothelial release of NO and loss of release of another vasodilator autacoid. Studies with mesulergine suggested that 5-HT 2 receptors in the endothelium mediate the release of both these vasodilator autacoids. However, the accuracy of this conclusion is dependent on the selectivity of mesulergine. Mesulergine is certainly a potent 5-HT 2 antagonist; the pEC 50 s at 5-HT 2A and 5-HT 2C receptors are both 9.19 (Hoyer et al., 1994) . However, it is inactive at 5-HT 4 receptors (Hoyer et al., 1994) and there is no evidence of activity at 5-HT 1 -like receptors. Thus it seems reasonably safe to deduce that inhibition of actions of sumatriptan by mesulergine represents evidence of 5-HT 2 receptor modulation. This is perhaps surprising since sumatriptan has been shown to be a selective 5-HT 1 agonist. Thus it would appear that sumatriptan is less selective than initially thought. The pEC 50 for sumatriptan at 5-HT 2C receptors has been found to be 4.3 (Hoyer et al., 1994) , so the much higher anity interaction that we observed between mesulergine and sumatriptan presumably results from 5-HT 2A receptor modulation.
The study is also limited by the lack of information on the nature of the second autacoid released from the endothelium that mediates sumatriptan-induced vasodilation. Prostacyclin and other cyclo-oxygenase products may be excluded since indomethacin has no eect on the endothelium-dependent NOindependent vasodilator eects of sumatriptan (unpublished observations from our laboratory). Further work is necessary to determine the identity of the second autacoid.
Finally, although sumatriptan did not cause endothelial NO release by itself, it did so in the presence of GR127935. This implies that the coupling of the mesulergine-sensitive endothelial receptors to endothelial nitric oxide synthase (NOS) is suppressed if endothelial 5-HT 1D agonism is extant. This suggests that the transductional linkage between mesulerginesensitive 5-HT 2 receptors and NOS may be uncoupled by 5-HT 1D agonism. The study is limited to the extent that the nature of this uncoupling mechanism was not examined.
Conclusions
Sumatriptan has complex actions on coronary¯ow in the guinea-pig isolated heart. The predominant eect is a 5-HT 1D receptor-mediated vasoconstriction. However, this eect is greatly enhanced if NO-dependent and NO-independent vasodilator eects, which appear to be mediated by 5-HT 2 receptors located on the coronary endothelium, are vitiated. This suggests that any tendency that sumatriptan may have to evoke pathogenic coronary constriction may be worsened by endothelial injury, through the loss of these actions. We found no evidence of sumatriptan-induced endothelium-independent coronary vasodilatation. Thus, in species in which vasoconstriction is not the predominant eect of sumatriptan in endothelium-intact hearts, the extent to which endothelial injury converts sumatriptan to a hazardous coronary vasoconstrictor is likely to be greater than was observed in guinea-pig hearts. In addition, in the guinea-pig heart, endothelial 5-HT 2 receptor-mediated NO release appears to be suppressed by extant 5-HT 1D agonism suggesting the possibility that 5-HT 1D agonism may uncouple the transductional linkage between 5-HT 2 receptors and nitric oxide synthase.
